Kymera Therapeutics

Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update

IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days,  enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring Clinical trials initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs Pre-clinical data presented at